Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting mTOR in Acute Lymphoblastic Leukemia

21 Feb 2019

Abstract excerpt

Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic disorder and constitutes approximately 25% of cancer diagnoses among children and teenagers. Pediatric patients have a favourable prognosis, with 5-years overall survival rates near 90%, while adult ALL still correlates with poorer survival. However, during the past few decades, the therapeutic outcome of adult ALL was significantly ameliorated,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Hematopoietic Stem Cell Transplantation
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30795552
DOI: 10.3390/cells8020190

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting mTOR in Acute Lymphoblastic LeukemiaPMID 30795552Read ↗

Targeting the mTOR Pathway in LeukemiaSemantic proximity Read ↗

Outlook on PI3K/AKT/mTOR inhibition in acute leukemiaSemantic proximity Read ↗

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivationSemantic proximity Read ↗

The mTOR Signaling Pathway in Pediatric NeuroblastomaSemantic proximity Read ↗

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and ImmunotherapySemantic proximity Read ↗

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screenSemantic proximity Read ↗

Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemiaSemantic proximity Read ↗

A kinase-independent role for CDK8 in BCR-ABL1+ leukemiaSemantic proximity Read ↗

The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic ResponseSemantic proximity Read ↗

Identification and targeting of novel CDK9 complexes in acute myeloid leukemiaSemantic proximity Read ↗

Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.